Present and future of personalized medicine in adult genitourinary tumors

Chiara Ciccarese, Matteo Santoni, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Alessandro Conti, Giampaolo Tortora, Stefano Cascinu, Rodolfo Montironi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The development of targeted agents has completely revolutionized the therapeutic scenario of genitourinary tumors. However, no biomarkers of tumor response or patient tolerability have been validated so far, and the selection of patients who may benefit from these approaches is still empirical. Significant advances in genomic sequencing and molecular characterization of these tumors have allowed identification of complex genomic abnormalities, thus increasing our knowledge on cancer biological landscapes and paving the way to the development of personalized strategies based on the patient's genomic and cancer's molecular profiles. This review is an overview of recent findings and emerging individualized therapies in patients with prostate, renal and bladder cancer, focusing on the promises and limitations of this approach in this setting.

Original languageEnglish
Pages (from-to)1381-1388
Number of pages8
JournalFuture Oncology
Volume11
Issue number9
DOIs
StatePublished - May 1 2015

Fingerprint

Precision Medicine
Neoplasms
Kidney Neoplasms
Tumor Biomarkers
Urinary Bladder Neoplasms
Patient Selection
Prostatic Neoplasms
Therapeutics

Keywords

  • bladder cancer
  • genitourinary tumors
  • personalized therapy
  • prostate cancer
  • renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ciccarese, C., Santoni, M., Massari, F., Cheng, L., Lopez-Beltran, A., Scarpelli, M., ... Montironi, R. (2015). Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 11(9), 1381-1388. https://doi.org/10.2217/fon.15.30

Present and future of personalized medicine in adult genitourinary tumors. / Ciccarese, Chiara; Santoni, Matteo; Massari, Francesco; Cheng, Liang; Lopez-Beltran, Antonio; Scarpelli, Marina; Conti, Alessandro; Tortora, Giampaolo; Cascinu, Stefano; Montironi, Rodolfo.

In: Future Oncology, Vol. 11, No. 9, 01.05.2015, p. 1381-1388.

Research output: Contribution to journalArticle

Ciccarese, C, Santoni, M, Massari, F, Cheng, L, Lopez-Beltran, A, Scarpelli, M, Conti, A, Tortora, G, Cascinu, S & Montironi, R 2015, 'Present and future of personalized medicine in adult genitourinary tumors', Future Oncology, vol. 11, no. 9, pp. 1381-1388. https://doi.org/10.2217/fon.15.30
Ciccarese C, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M et al. Present and future of personalized medicine in adult genitourinary tumors. Future Oncology. 2015 May 1;11(9):1381-1388. https://doi.org/10.2217/fon.15.30
Ciccarese, Chiara ; Santoni, Matteo ; Massari, Francesco ; Cheng, Liang ; Lopez-Beltran, Antonio ; Scarpelli, Marina ; Conti, Alessandro ; Tortora, Giampaolo ; Cascinu, Stefano ; Montironi, Rodolfo. / Present and future of personalized medicine in adult genitourinary tumors. In: Future Oncology. 2015 ; Vol. 11, No. 9. pp. 1381-1388.
@article{f548b9370f53405c83c4fa82def154a8,
title = "Present and future of personalized medicine in adult genitourinary tumors",
abstract = "The development of targeted agents has completely revolutionized the therapeutic scenario of genitourinary tumors. However, no biomarkers of tumor response or patient tolerability have been validated so far, and the selection of patients who may benefit from these approaches is still empirical. Significant advances in genomic sequencing and molecular characterization of these tumors have allowed identification of complex genomic abnormalities, thus increasing our knowledge on cancer biological landscapes and paving the way to the development of personalized strategies based on the patient's genomic and cancer's molecular profiles. This review is an overview of recent findings and emerging individualized therapies in patients with prostate, renal and bladder cancer, focusing on the promises and limitations of this approach in this setting.",
keywords = "bladder cancer, genitourinary tumors, personalized therapy, prostate cancer, renal cell carcinoma, targeted therapy",
author = "Chiara Ciccarese and Matteo Santoni and Francesco Massari and Liang Cheng and Antonio Lopez-Beltran and Marina Scarpelli and Alessandro Conti and Giampaolo Tortora and Stefano Cascinu and Rodolfo Montironi",
year = "2015",
month = "5",
day = "1",
doi = "10.2217/fon.15.30",
language = "English",
volume = "11",
pages = "1381--1388",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Present and future of personalized medicine in adult genitourinary tumors

AU - Ciccarese, Chiara

AU - Santoni, Matteo

AU - Massari, Francesco

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Scarpelli, Marina

AU - Conti, Alessandro

AU - Tortora, Giampaolo

AU - Cascinu, Stefano

AU - Montironi, Rodolfo

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The development of targeted agents has completely revolutionized the therapeutic scenario of genitourinary tumors. However, no biomarkers of tumor response or patient tolerability have been validated so far, and the selection of patients who may benefit from these approaches is still empirical. Significant advances in genomic sequencing and molecular characterization of these tumors have allowed identification of complex genomic abnormalities, thus increasing our knowledge on cancer biological landscapes and paving the way to the development of personalized strategies based on the patient's genomic and cancer's molecular profiles. This review is an overview of recent findings and emerging individualized therapies in patients with prostate, renal and bladder cancer, focusing on the promises and limitations of this approach in this setting.

AB - The development of targeted agents has completely revolutionized the therapeutic scenario of genitourinary tumors. However, no biomarkers of tumor response or patient tolerability have been validated so far, and the selection of patients who may benefit from these approaches is still empirical. Significant advances in genomic sequencing and molecular characterization of these tumors have allowed identification of complex genomic abnormalities, thus increasing our knowledge on cancer biological landscapes and paving the way to the development of personalized strategies based on the patient's genomic and cancer's molecular profiles. This review is an overview of recent findings and emerging individualized therapies in patients with prostate, renal and bladder cancer, focusing on the promises and limitations of this approach in this setting.

KW - bladder cancer

KW - genitourinary tumors

KW - personalized therapy

KW - prostate cancer

KW - renal cell carcinoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84929247016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929247016&partnerID=8YFLogxK

U2 - 10.2217/fon.15.30

DO - 10.2217/fon.15.30

M3 - Article

VL - 11

SP - 1381

EP - 1388

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 9

ER -